Thrombolysis in strokes carries large risk

BMJ 1997; 315 doi: 10.1136/bmj.315.7108.563h (Published 6 September 1997)
Cite this as: BMJ 1997;315:563.9

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Kamran Abbasi
  1. A1

    Thrombolysis in acute ischaemic stroke carries a substantial risk and uncertain benefit, according to a systematic review of the evidence.

    In the United States tissue plasminogen activator (tPA) is licensed for use within three hours of a stroke, and its use in this setting is recommended by American medical organisations. However, Dr Joanna Wardlaw, senior lecturer in the department of neuroradiology at the University of Edinburgh, and her team of researchers, concludes that the evidence does not support such an approach and more randomised trials are needed (Lancet 1997;350:607-14).

    Her team carried …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL